The drugmaker also saw revenue grow to $6.06 billion in the third quarter, compared to $5.66 billion in the same period in 2017. The growth was attributed to its strong pharmaceutical portfolio performance.
“Lilly delivered strong financial results in the third quarter. Revenue growth driven by greater use of our newest medicines, coupled with prudent expense management, led to strong earnings per share growth,” Eli Lilly Chairman and CEO David Ricks told the WSJ.
The company expects annual revenue of $24.3 billion to $24.5 billion.
More articles on pharmacy:
CVS Health posts $1.4B profit, expects Aetna deal to close by Thanksgiving
CVS pilots membership program to take on Amazon
Insys wants to sell off opioid-related assets
